Int J Biol Sci 2022; 18(12):4731-4743. doi:10.7150/ijbs.72482 This issue

Review

SARS-CoV-2 and the Nucleus

Mengqi Chen, Yue Ma, Wakam Chang

Department of Biomedical Sciences, Faculty of Health Sciences, University of Macau, Taipa, Macau, China

This is an open access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/). See http://ivyspring.com/terms for full terms and conditions.
Citation:
Chen M, Ma Y, Chang W. SARS-CoV-2 and the Nucleus. Int J Biol Sci 2022; 18(12):4731-4743. doi:10.7150/ijbs.72482. Available from https://www.ijbs.com/v18p4731.htm

File import instruction

Abstract

Graphic abstract

The ongoing COVID-19 pandemic is caused by an RNA virus, SARS-CoV-2. The genome of SARS-CoV-2 lacks a nuclear phase in its life cycle and is replicated in the cytoplasm. However, interfering with nuclear trafficking using pharmacological inhibitors greatly reduces virus infection and virus replication of other coronaviruses is blocked in enucleated cells, suggesting a critical role of the nucleus in virus infection. Here, we summarize the alternations of nuclear pathways caused by SARS-CoV-2, including nuclear translocation pathways, innate immune responses, mRNA metabolism, epigenetic mechanisms, DNA damage response, cytoskeleton regulation, and nuclear rupture. We consider how these alternations contribute to virus replication and discuss therapeutic treatments that target these pathways, focusing on small molecule drugs that are being used in clinical studies.

Keywords: SARS-CoV-2, nuclear transport, innate immunity, epigenetics, cilia, DNA damage